Syndax Pharmaceuticals
SNDX
17.03
-0.34
-1.96%
Syndax Pharmaceuticals
US · SNDX
#2947 by market cap
Listed 2016
17.03
-0.34
-1.96%
Live - 5344 symbols - heartbeat 379s ago
· 2026-10-08 07:42
Pre-market
16.80
-1.35%
After-hours
17.20
+1.00%
- Market cap
- 1.52B
- P/E (TTM)i
- -6.78
- P/Bi
- 100.77
- EPSi
- -3.29
- Div yieldi
- 0.00%
- 52W posi
- 32%
Reader sentiment
Are you bullish or bearish on SNDX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -2.47, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +627.84% YoY
Margins
- Gross margin
- 95.96%
- Operating margin
- -158.45%
- Net margin
- -165.60%
Key ratios & quality
- Enterprise valuei
- 1.45B
- Altman Z-Scorei
- -2.47
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.52M | 1.52M | 1.52M | 139.71M | 0 | 0 | 23.68M | 172.35M |
| Gross profit | -- | -- | -- | -- | 0 | 0 | 22.85M | 165.38M |
| Selling & admin expenses | 17.29M | 16.06M | 22.51M | 25.24M | 33.26M | 66.92M | 120.88M | 179.68M |
| Research & development | 60.11M | 42.99M | 50.44M | 88.25M | 118.50M | 163.03M | 241.65M | 258.78M |
| Operating profit | -75.88M | -57.54M | -71.42M | 26.22M | -151.76M | -229.95M | -339.67M | -273.08M |
| Pretax profit | -73.96M | -56.05M | -73.16M | 24.93M | -149.34M | -209.36M | -318.76M | -285.42M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -73.96M | -56.05M | -73.16M | 24.93M | -149.34M | -209.36M | -318.76M | -285.42M |
| Basic EPS | -3 | -2 | -2 | 0 | -2 | -3 | -4 | -3 |
| Diluted EPS | -2.92 | -1.84 | -1.87 | 0.46 | -2.46 | -2.98 | -3.72 | -3.29 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 20.04M | 37.96M | 45.87M | 68.73M | 64.86M | 72.79M |
| Gross profit | 19.16M | 36.68M | 43.77M | 66.02M | 62.23M | 69.58M |
| Selling & admin expenses | 41.03M | 43.81M | 44.92M | 49.93M | 37.59M | 41.54M |
| Research & development | 61.64M | 62.23M | 56.28M | 78.64M | 58.85M | 68.04M |
| Operating profit | -83.76M | -69.35M | -57.43M | -62.55M | -34.20M | -40.00M |
| Pretax profit | -84.85M | -71.85M | -60.72M | -68.01M | -42.67M | -49.36M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -84.85M | -71.85M | -60.72M | -68.01M | -42.67M | -49.36M |
| Basic EPS | -1 | -1 | -1 | -1 | 0 | -1 |
| Diluted EPS | -0.98 | -0.83 | -0.70 | -0.78 | -0.48 | -0.55 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 83.35M | 62.33M | 298.86M | 448.40M | 489.79M | 580.88M | 603.06M | 528.08M |
| Cash & ST investments | 80.91M | 59.78M | 293.07M | 446.83M | 484.40M | 577.58M | 582.91M | 413.69M |
| Inventory | -- | -- | -- | -- | -- | 0 | 366.00K | 32.75M |
| Total assets | 83.94M | 63.53M | 300.61M | 449.66M | 497.24M | 612.88M | 724.82M | 529.71M |
| Total current liabilities | 16.11M | 18.37M | 18.87M | 20.68M | 29.07M | 58.10M | 103.55M | 120.12M |
| Short-term debt | -- | 478.00K | 2.60M | 362.00K | 439.00K | 1.05M | 12.60M | 472.00K |
| Long-term debt | -- | -- | 17.83M | 19.90M | -- | -- | 331.57M | 343.91M |
| Total liabilities | 30,891,000.00 | 31,925,000.00 | 48,425,000.00 | 41,289,000.00 | 29,787,000.00 | 58,684,000.00 | 436,692,000.00 | 465,076,000.00 |
| Total equity | 53.05M | 31.60M | 252.19M | 408.37M | 467.45M | 554.20M | 288.12M | 64.63M |
| Retained earnings | -439.42M | -495.47M | -568.63M | -543.70M | -693.04M | -902.40M | -1.22B | -1.51B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 548.75M | 531.68M | 529.83M | 528.08M | 471.18M | 675.04M |
| Cash & ST investments | 516.31M | 468.71M | 454.17M | 413.69M | 361.24M | 554.27M |
| Inventory | 4.66M | 17.70M | 25.00M | 32.75M | 34.95M | 33.16M |
| Total assets | 640.71M | 596.15M | 551.79M | 529.71M | 472.67M | 703.65M |
| Total current liabilities | 94.55M | 112.99M | 114.19M | 120.12M | 86.17M | 99.68M |
| Short-term debt | 384.00K | 350.00K | 331.00K | 472.00K | 488.00K | 506.00K |
| Long-term debt | -- | -- | -- | 343.91M | 343.97M | 588.12M |
| Total liabilities | 425,648,000.00 | 438,725,000.00 | 436,362,000.00 | 465,076,000.00 | 431,046,000.00 | 688,553,000.00 |
| Total equity | 215.06M | 157.42M | 115.43M | 64.63M | 41.62M | 15.10M |
| Retained earnings | -1.31B | -1.38B | -1.44B | -1.51B | -1.55B | -1.60B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -68.53M | -50.61M | -71.26M | 29.13M | -133.68M | -160.60M | -274.90M | -322.98M |
| Depreciation & amortization | 78.00K | 92.00K | 89.00K | 43.00K | 33.00K | 12.00K | 8.00K | 6.00K |
| Free cash flow | -68.72M | -50.61M | -71.26M | 29.00M | -133.68M | -160.60M | -274.90M | -323.17M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 15.50M | 28.21M | 278.06M | 86.34M | 181.39M | 258.09M | 0 | 0 |
| Ending cash balance | 33.99M | 24.72M | 115.36M | 222.08M | 74.47M | 295.61M | 154.30M | 135.03M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -95.16M | -87.80M | -70.54M | -69.49M | -50.35M | -30.27M |
| Depreciation & amortization | 0 | 0 | 3.00K | 3.00K | 4.00K | 5.00K |
| Free cash flow | -95.16M | -87.80M | -70.67M | -69.54M | -50.35M | -30.31M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 154.21M | 108.85M | 117.03M | 135.03M | 131.00M | 336.58M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -94.00 | -132.43 | -54.31 | 7.55 | -34.10 | -40.98 | -75.69 | -161.83 |
| ROA %i | -66.90 | -76.02 | -42.33 | 6.64 | -31.54 | -37.72 | -47.66 | -45.50 |
| ROIC %i | -94.00 | -129.68 | -49.50 | 7.53 | -33.87 | -44.96 | -57.14 | -52.57 |
| 5-year avg ROE %i | -- | -- | -- | -67.54 | -61.46 | -50.86 | -39.51 | -61.01 |
| EBIT margin %i | -5,001.71 | -3,792.95 | -4,667.17 | 19.20 | -- | -- | -1,325.29 | -146.00 |
| FCF / sales %i | -- | -- | -- | 20.76 | -- | -- | -- | -- |
| Current ratioi | 5.18 | 3.39 | 15.84 | 21.68 | 16.85 | 10.00 | 5.82 | 4.40 |
| Quick ratioi | 5.04 | 3.26 | 15.54 | 21.62 | 16.81 | 9.96 | 5.76 | 4.03 |
| Debt / assetsi | 0.00 | 1.41 | 6.83 | 4.66 | 0.23 | 0.27 | 47.70 | 65.21 |
| LT debt / equityi | -- | 1.33 | 7.11 | 5.05 | 0.15 | 0.11 | 115.62 | 533.75 |
| Interest coveragei | -- | -- | -30.04 | 14.13 | -46.61 | -1,005.54 | -63.67 | -7.45 |
| Revenue CAGR (3Y) %i | 34.25 | 7.53 | -10.39 | 351.59 | -- | -- | -44.66 | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -93.70 | -113.22 | -129.32 | -161.83 | -189.53 | -255.93 |
| ROA %i | -55.96 | -62.43 | -63.74 | -45.50 | -43.70 | -33.97 |
| ROIC %i | -96.96 | -114.35 | -127.25 | -52.57 | -74.44 | -51.15 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -727.96 | -403.23 | -253.88 | -146.00 | -94.70 | -70.71 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.80 | 4.71 | 4.64 | 4.40 | 5.47 | 6.77 |
| Quick ratioi | 5.69 | 4.48 | 4.35 | 4.03 | 4.90 | 6.29 |
| Debt / assetsi | 0.29 | 0.28 | 0.28 | 65.21 | 73.07 | 83.76 |
| LT debt / equityi | 0.68 | 0.84 | 1.03 | 533.75 | 828.58 | 3,900.10 |
| Interest coveragei | -24.63 | -15.15 | -9.74 | -7.45 | -5.47 | -4.21 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Syndax Pharmaceuticals100.00%
Quote time 2026-10-08 07:42:13 · For reference only, not investment advice and not tailored to your situation.